Latest Updates of Companies in the Tissue Regenerative Therapy Market with Key Development
Company Overview
| Company | Headquarters | Latest Update |
| Novartis AG | Switzerland | In October 2025, Novartis presents momentous immunology developments in ACR congress with novel data in challenging autoimmune diseases. |
| Gilead Sciences, Inc. | United States | Gilead Sciences, Inc. is significantly focused on expanding its cell therapy portfolio and investing in In Vivo therapeutics, which are thoroughly related to the advancement in tissue regeneration and, precisely, CAR-T in solid tumors. |
| Smith & Nephew plc | United States | In September 2025, Smith Nephew is a portfolio medical technology business focused on the repair, regeneration, and replacement of soft and hard tissue. |
| Medtronic plc | United States | Medtronic explores the next frontier in medical care: regenerative medicine. |
| Stryker Corporation | United States | Stryker unveils novel intracranial base catheter to streamline neurovascular admission and therapy delivery. |
| Integra LifeSciences Corporation | United States | Integra LifeSciences Corporation is focusing heavily on rehabilitating its supply chain and progressing its portfolio of tissue regenerative therapies. |
Value Chain Analysis: Tissue Regenerative Therapy Market
R&D:
- Major R&D processes include cell source engineering and manipulation, biomaterials and scaffold fabrication, bioactive factor discovery and delivery, genetic engineering and precision medicine, bioprocess and translational research
- Key Players: Pfizer and Novartis
Manufacturing Processes:
- Manufacturing processes for tissue regeneration therapies follow a structured workflow that integrates biological components with engineering processes to create functional substitutes for injured tissues
- Key Players: MiMedx Group and Integra LifeSciences
Patient Services:
- Tissue regeneration therapy includes an inclusive suite of patient solutions aimed at repairing, replacing, or regenerating damaged cells, tissues, and organs.
- Key Players: Vericel Corporation and Organogenesis Inc.
Market Growth
The global tissue regenerative therapy market size was estimated at USD 15.04 billion in 2025 and is predicted to increase from USD 16.85 billion in 2026 to approximately USD 46.88 billion by 2035, expanding at a CAGR of 12.04% from 2026 to 2035.
Recent Developments in the Tissue Regenerative Therapy Market
- In December 2025, Cipla announced the launch of Ciplostem, an allogeneic mesenchymal stromal cell therapy for Knee Osteoarthritis, approved by the Drug Controller General of India (DCGI). The therapy has been developed by Semeiotics Research and targets Grade II and Grade III Knee OA.
- In August 2025, Adia Nutrition Inc. announced the launch of its second nationwide television campaign, spotlighting the regenerative stem cell treatments available at its Winter Park, Florida, clinic.
Bring every Tissue Regenerative Therapy Market Data together under one roof - Access the Dashboard
Keypoints
- Company Overview
- Locations Subsidiaries/Geographic reach
- Key Executives
- Company Financials
- Patents registered
- SWOT Analysis
- Applications Catered
- Strategic collaborations
- Recent Developments
- Competitive Benchmarking
